<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05626166</url>
  </required_header>
  <id_info>
    <org_study_id>36031/11/22</org_study_id>
    <nct_id>NCT05626166</nct_id>
  </id_info>
  <brief_title>the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis</brief_title>
  <official_title>Clinical Study Evaluating the Efficacy and Safety of Diosmin in Patients With Ulcerative Colitis Treated With Mesalamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled study evaluating diosmin tablets administered daily for 3&#xD;
      months. The purpose of the study is to evaluate the efficacy and safety of diosmin in the&#xD;
      treatment of mild to moderately active ulcerative colitis. Disease activity will be measured&#xD;
      using modified truelove and witt's classification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims at evaluating the efficacy and safety of diosmin as add-on therapy to&#xD;
      mesalamine in patients with mild to moderate ulcerative colitis.&#xD;
&#xD;
      This proof of concept study will be designed to be a randomized, double-blind, placebo&#xD;
      controlled parallel study. The study will be conducted on 60 patients with mild to moderate&#xD;
      ulcerative colitis receiving mesalamine. The patient will be followed for 3 months.&#xD;
&#xD;
      The patients will be randomised into the following two groups:&#xD;
&#xD;
      Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus&#xD;
      placebo tablets twice daily for 3 months.&#xD;
&#xD;
      Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus&#xD;
      diosmin 600 mg twice daily for 3 months.&#xD;
&#xD;
      All participants included in this study will be subjected to the following:&#xD;
&#xD;
        1. Demography, history, and physical examination&#xD;
&#xD;
        2. Blood sample collection and biochemical assessment At baseline and after the&#xD;
           intervention, 10 ml of venous blood will be withdrawn from each participant.&#xD;
&#xD;
      3 ml of blood will be used for immediate determination of routine parameters including:&#xD;
&#xD;
        -  Hemoglobin concentration.&#xD;
&#xD;
        -  Ertherythrocyte sedimentation rate (ESR).&#xD;
&#xD;
        -  Prothrombin time.&#xD;
&#xD;
      Two ml of blood will be immediately centrifuged at 3000 rpm for 10 min for immediate&#xD;
      determination of:&#xD;
&#xD;
      - Serum albumin&#xD;
&#xD;
      The remaining 5 ml of blood will be used for the analysis of the biological parameters which&#xD;
      include:&#xD;
&#xD;
        -  Malondialdehyde (MDA) as oxidative stress marker (colorimetry).&#xD;
&#xD;
        -  Tumor necrosis factor-alpha (TNF-α) as pro inflammatory marker (ELISA).&#xD;
&#xD;
        -  Caspase-3 as a potential marker for apoptosis (ELISA). 3. Clinical assessment&#xD;
&#xD;
      Clinical assessment will be done through determination of:&#xD;
&#xD;
      A. Disease severity which will be assessed according to the modified Truelove and Witt's&#xD;
      classification.&#xD;
&#xD;
      B. The activity index (AI) for ulcerative colitis which is expressed as follows:&#xD;
&#xD;
      AI = 60 x blood stool + 13 x bowel movements (frequency of defection) + 0.5 x ESR - 4 x Hb -&#xD;
      15 x albumin + 200.&#xD;
&#xD;
      C. Health-related Quality of Life (HRQoL) using The Short Inflammatory Bowel Disease&#xD;
      Questionnaire (SIBDQ).&#xD;
&#xD;
      D. Assessement of pain score through the brief pain inventory short form &quot;BPI-SF&quot; worst item.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2022</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This proof of concept study will be designed to be a randomized, double-blind, placebo controlled parallel study. The study will be conducted on 60 patients with mild to moderate ulcerative colitis receiving mesalamine. Patients will be recruited from Tropical Medicine Department, Tanta University Hospital, Tanta, Egypt. The patient will be followed for 3 months. The blindness will be maintained by the similarity in appearance, color and shape between placebo and diosmin tablets. The patients will be randomized in a 1:1 ratio by neutral researcher using sealed envelopes methods with assignment codes into the following two groups: Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.&#xD;
Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This proof of concept study will be designed to be a randomized, double-blind, placebo controlled parallel study, The blindness will be maintained by the similarity in appearance, color and shape between placebo and diosmin tablets.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the change in Truelove and Witt's classification.</measure>
    <time_frame>at baseline then after 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>the change in health related quality of life (HRQoL) questionnaire</measure>
    <time_frame>at baseline then after 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change in the measured biological parameters (TNF alpha, MDA, caspase-3)</measure>
    <time_frame>at baseline then after 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group I (Control group; n=30) which will receive mesalamine 1000 mg three times daily plus placebo tablets twice daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diosmin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group II: (Diosmin group; n=30) which will receive mesalamine 1000 mg three times daily plus diosmin 600 mg twice daily for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets twice daily</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>diosmin 600 mg twice daily</description>
    <arm_group_label>diosmin group</arm_group_label>
    <other_name>diosimax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old.&#xD;
&#xD;
          -  Both male and female sex.&#xD;
&#xD;
          -  Newly diagnosed patients with mild and moderate ulcerative colitis and treated with&#xD;
             5-aminosalicylic acid (mesalamine).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with severe ulcerative colitis.&#xD;
&#xD;
          -  Patients with colorectal cancer.&#xD;
&#xD;
          -  Patients on rectal or systemic steroids.&#xD;
&#xD;
          -  Patients on immunosuppressants or biological therapies.&#xD;
&#xD;
          -  Patients with previously failed treatment with sulphasalazine.&#xD;
&#xD;
          -  Patients with known allergy to study medications.&#xD;
&#xD;
          -  History of complete or partial colectomy.&#xD;
&#xD;
          -  Patients with heart diseases and arrhythmia.&#xD;
&#xD;
          -  Patients on blood thinning agents.&#xD;
&#xD;
          -  Patients on anticoagulants (warfarin), anticonvulsants (carbamazepine and phenytoin),&#xD;
             muscle relaxants (chlorzoxazone) and non-steroidal anti-inflammatory drugs&#xD;
             (diclofenac).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tarek M mostafa, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>amira B ismail, master</last_name>
    <phone>00201142760505</phone>
    <email>amira7794.aa@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tanta university hospital</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanta University Hospitals</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 22, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2022</study_first_posted>
  <last_update_submitted>April 10, 2023</last_update_submitted>
  <last_update_submitted_qc>April 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Amira B ismail</investigator_full_name>
    <investigator_title>clinical pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

